HomeCompareJPS vs JNJ

JPS vs JNJ: Dividend Comparison 2026

JPS yields 6.92% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $8.7K in total portfolio value· pulled ahead in Year 7
10 years
JPS
JPS
● Live price
6.92%
Share price
$6.21
Annual div
$0.43
5Y div CAGR
-36.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.7K
Annual income
$8.15
Full JPS calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — JPS vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJPSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JPS + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JPS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JPS
Annual income on $10K today (after 15% tax)
$588.57/yr
After 10yr DRIP, annual income (after tax)
$6.93/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JNJ beats the other by $4,030.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JPS + JNJ for your $10,000?

JPS: 50%JNJ: 50%
100% JNJ50/50100% JPS
Portfolio after 10yr
$26.1K
Annual income
$2,379.01/yr
Blended yield
9.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

JPS
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JPS buys
0
JNJ buys
0
No recent congressional trades found for JPS or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJPSJNJ
Forward yield6.92%2.14%
Annual dividend / share$0.43$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-36.5%28%
Portfolio after 10y$21.7K$30.5K
Annual income after 10y$8.15$4,749.88
Total dividends collected$1.2K$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JPS vs JNJ ($10,000, DRIP)

YearJPS PortfolioJPS Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,140$439.69$10,594$274.49+$546.00JPS
2$12,210$290.68$11,294$360.69+$916.00JPS
3$13,254$189.08$12,133$476.91+$1.1KJPS
4$14,304$121.81$13,156$635.42+$1.1KJPS
5$15,383$78.01$14,432$854.61+$951.00JPS
6$16,509$49.79$16,056$1,162.76+$453.00JPS
7← crossover$17,697$31.71$18,175$1,604.53$478.00JNJ
8$18,956$20.17$21,009$2,252.68$2.1KJNJ
9$20,295$12.82$24,911$3,229.73$4.6KJNJ
10$21,724$8.15$30,458$4,749.88$8.7KJNJ

JPS vs JNJ: Complete Analysis 2026

JPSStock

Nuveen Preferred Securities Income Fund is a closed-ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Spectrum Asset Management, Inc. It invests in the fixed income markets of the United States. The fund primarily invests in investment grade preferred debt securities, convertible debt securities, and convertible preferred securities that are rated BBB/Baa or better by S&P, Moody's, or Fitch. It was formerly known as Nuveen Quality Preferred Income Fund 2. Nuveen Preferred Securities Income Fund was formed on June 24, 2002 and is domiciled in the United States.

Full JPS Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this JPS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JPS vs SCHDJPS vs JEPIJPS vs OJPS vs KOJPS vs MAINJPS vs ABBVJPS vs MRKJPS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.